FindTrial
Sign In

Safety and effectiveness of rosuvastatin versus rosuvastatin with fenofibrate in patients with dyslipidemia.

A comparative study to evaluate the efficacy and safety of rosuvastatin or in combination of rosuvastatin with fenofibrate in patients with dyslipidemia at tertiary care centre. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070696
Enrollment
262
Registered
2024-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: R0SUVASTATIN and FENOFIBRATE: 10 mg and 160 mg respectively for 3 months Control Intervention1: ROSUVASTATIN: 10 mg for 3 months.

Sponsors

Dr Shivam Yadav
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Either gender aged 18 to 70 years . Patients giving written informed consent will be taken. Hypertensive patients.

Exclusion criteria

Exclusion criteria: Patient not willing to participate in the study. Active liver disease. Preexisting gallbladder disease. Type 1 diabetes mellitus. Thyroid dysfunction. Type 2 diabetes mellitus. Any malignancies.

Design outcomes

Primary

MeasureTime frame
Quality of lifeTimepoint: Baseline, 2 months, 3 months—

Secondary

MeasureTime frame
Adverse drug reactionTimepoint: At 2nd and 3rd month—

Countries

India

Contacts

Public ContactDr Shivam Yadav

Baba Raghav Das Medical College, Gorakhpur

dranilk194@gmail.com8303060884

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026